Pharmacological research aimed at targeting MYB–NFIB fusion for ACC is lacking; however, a trial targeting MYB-NFIB fusion via TetMYB vaccine and anti-programmed death 1 (PD1) antibody is currently in phase 1 [44]. Here, MYB is linked to adrenal cortex carcinoma.